Business Context and Reporting Period
This Form 8-K is a current report filed by Eliem Therapeutics, Inc. (trading symbol: ELYM) on August 26, 2024. The filing discloses the appointment of a new Chief Operating Officer and details the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: $500,000 per year.
- Annual Discretionary Bonus: Up to 45.0% of the annualized base salary.
- Equity Grant (Stock Options): 465,000 shares at the closing price on the effective date.
- Equity Grant (RSUs): 77,500 restricted stock units.
Material Changes
The primary material change is the appointment of Brett Kaplan, M.D., as Chief Operating Officer, effective August 26, 2024. Dr. Kaplan previously served as President, Chief Financial and Corporate Development Officer of Chroma Medicine, Inc. (June 2021–August 2024) and Chief Financial Officer of Prevail Therapeutics Inc. (acquired by Eli Lilly and Company).
Guidance, Outlook, and Risks
The filing does not provide financial guidance or operational outlook. Key contingencies and risks relate to the executive employment agreement:
- Termination without Cause/Good Reason (Standard): Entitles the executive to nine months of base salary, unpaid prior year bonus, nine months of COBRA coverage, and acceleration of equity vesting scheduled within six months of termination.
- Termination without Cause/Good Reason (Change in Control): If occurring within 12 months of a change in control, the executive is entitled to 12 months of base salary, the target annual bonus, unpaid prior year bonus, 12 months of COBRA coverage, and full acceleration of all unvested time-based equity awards.
- Indemnification: The Company has agreed to indemnify Dr. Kaplan for certain expenses, judgments, and penalties incurred in actions arising from his service to the Company.
Investor Verification Checklist
- Verify the closing stock price on August 26, 2024, to calculate the exercise price of the 465,000 stock options granted.
- Review the full text of the Offer Letter (Exhibit 10.1) for specific definitions of "cause," "good reason," and "change in control."
- Confirm the vesting schedule details for the 77,500 RSUs (25% annually over four years) and the stock options (25% cliff vesting after one year, then monthly).
- Assess the impact of the new executive's background in finance and corporate development on the company's strategic direction.